ClinicalTrials.gg
Status unknownNCT05826769Updated Apr 24, 2023

To Assess the Efficacy of Early Administration of Energy Enriched and Protein Enriched Formula in Post Cardiac Repair Infants: a Randomized Controlled Trial, Comparative Study

An interventional study of Energy- Protein Enriched Nutritional Formula in Congenital Heart Disease in Children, Post-cardiac Surgery and Malnutrition, Infant, sponsored by King Faisal Specialist Hospital & Research Centre, Jeddah. Status unknown at 1 site in Saudi Arabia. Open to participants aged 4 Weeks to 1 Year. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by King Faisal Specialist Hospital & Research Centre, Jeddah · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jul 2021, registered Apr 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
4 Weeks to 1 Year
Sex
All
01

Study summary

Congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery. An open, 2-arm, randomized controlled trials will be conducted to assess the efficacy of early administration of energy enriched and protein enriched formula in post cardiac repair infants. The expected primary outcome is that intervention group will have good tolerance to feeding and the secondary outcome is the significant weight gain rate (weight velocity) in comparing to control groups

Read the detailed description

Due to a high incidence of 9/1000 live births, congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. Numerous clinical trials have been conducted (Zhang H et al., 2018; Scheeffer. et al., 2019) and were designed to explore the effects of early introduction of Energy Enriched and Protein Enriched formula (EP) to infants with CHD. The research found that feeding EP is correlated with improved weight gain and nutritional status, and also a decrease in Hospital Length Of Stay (HLOS) as well as antibiotic use, but this also causes increased feeding discomfort. The signs of feeding discomfort, on the other hand, were improved by medication and had little effect on feeding progress.

The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery.

02

Conditions studied

  • Congenital Heart Disease in Children
  • Post-cardiac Surgery
  • Malnutrition, Infant

Keywords

  • Energy Protein, Enriched
  • Enteral Nutrition
  • Cardiac Repair
03

In context

Infant Nutrition Disorders

67 studies on the registry are indexed under Infant Nutrition Disorders; 14 are open to participants now.

This study's planned enrollment of 60 is below the median of 180 across 46 interventional studies indexed under Infant Nutrition Disorders.

Browse Infant Nutrition Disorders studies →

Lead sponsor

King Faisal Specialist Hospital & Research Centre, Jeddah is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Weeks to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. infants born at term, age between 4 weeks and 12 months
  2. post congenital heart surgery (RACHS score 2)

Exclusion criteria

Exclusion Criteria:

  1. syndromic patients
  2. if patient is on parenteral nutrition (PN)
  3. premature
  4. combined inherited metabolic or chromosomal diseases
  5. liver and kidney dysfunction before enrollment (index >2 times the )
  6. upper GI activity, vomiting, diarrhea, bloating, and other symptoms before enrollment
  7. breastfeeding patients.
  8. cow's milk allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Energy- Protein Enriched Nutritional Formula

    Liquid, ready-to-use Energy-Protein nutrition formula with energy density of 1 kCal/mL (EP formula)

    Dietary Supplement: Energy- Protein Enriched Nutritional Formula

  • No intervention
    Standard Nutritional Formula

    Polymeric formula stage-1 and stage-2 for infants aged 0-6 months and 6-12 months accordingly, providing 0.67 kCal/mL (S-1/S-2 formula)

Interventions

  • Dietary supplementEnergy- Protein Enriched Nutritional Formula

    EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.

    Also known as: High Calorie High Protein Nutritional Formula

06

What researchers measure

Primary outcomes

  1. after admission in ICU, will measure the Tolerability

    Gastric tolerance

    Time frame: 5 days

Secondary outcomes

  1. Weight gain rate

    Weight velocity

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • KFSHRC
    Jeddah, Outside North America, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05826769
Lead sponsor
King Faisal Specialist Hospital & Research Centre, Jeddah
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Jul 21, 2021
Primary completion
Jul 27, 2022
Completion
Mar 12, 2024 (estimated)
Last update
Apr 24, 2023

Study contacts

Abrar Shirbini
Contact
ashirbini@kfshrc.edu.sa
00966126677777 ext. 42401
Ahmed Elmahrouk
Contact
ael-mahrouk@kfshrc.edu.sa
00966126677777 ext. 40250

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion